NCT02583061 Toronto Gestational Glucose Tolerance Cohort
| NCT ID | NCT02583061 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mount Sinai Hospital, Canada |
| Condition | Type 2 Diabetes, Gestational Diabetes, Pre-diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2003-09 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2003-09 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this prospective observational cohort study, women representing the full spectrum of gestational glucose tolerance status are undergoing longitudinal cardiometabolic characterization at regular intervals in the years after the index pregnancy.
Eligibility Criteria
Inclusion Criteria: * Pregnant women Exclusion Criteria: * Pre-existing diabetes before the index pregnancy
Contact & Investigator
Ravi Retnakaran, MD
PRINCIPAL INVESTIGATOR
MOUNT SINAI HOSPITAL
Frequently Asked Questions
Who can join the NCT02583061 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 60 Years, studying Type 2 Diabetes, Gestational Diabetes, Pre-diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02583061 currently recruiting?
Yes, NCT02583061 is actively recruiting participants. Contact the research team at ravi.retnakaran@sinaihealth.ca for enrollment information.
Where is the NCT02583061 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT02583061 clinical trial?
NCT02583061 is sponsored by Mount Sinai Hospital, Canada. The principal investigator is Ravi Retnakaran, MD at MOUNT SINAI HOSPITAL. The trial plans to enroll 350 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.